Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Estrella Immunopharma, Inc.

Accession: 0001213900-26-113912

Filed: 2026-10-29

Period: 2026-10-25

CIK: 0001844417

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0310209-8k_estrella.htm (Primary)

EX-10.1 — EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND CYNTHIA PUSSINEN (ea031020901ex10-1.htm)

EX-10.2 — AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND CHENG LIU, PH.D (ea031020901ex10-2.htm)

EX-10.3 — AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND JIANDONG (PETER) XU (ea031020901ex10-3.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0310209-8k_estrella.htm · Sequence: 1

false

0001844417

0001844417

2026-10-25

2026-10-25

0001844417

ESLA:CommonStockParValue0.0001PerShareMember

2026-10-25

2026-10-25

0001844417

ESLA:WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember

2026-10-25

2026-10-25

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 25, 2026

ESTRELLA IMMUNOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40608

86-1314502

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

5858 Horton Street, Suite 370

Emeryville, California

94608

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (510) 318-9098

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

ESLA

The Nasdaq Stock Market LLC

Warrants, each warrant exercisable for one share of Common Stock, each at an exercise price of $11.50 per share

ESLAW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

On October 25, 2026, the Board

of Directors (the “Board”) of Estrella Immunopharma, Inc. (the “Company”) appointed Cynthia Pussinen, age 57,

as Chief Executive Officer of the Company and as a Class I director and Chairperson of the Board, in each case effective October 25, 2026.

Ms. Pussinen is not expected to be named to any committee of the Board. Effective October 25, 2026, Cheng Liu, Ph.D., ceased to serve

as Chief Executive Officer and was appointed Chief Scientific Officer; Dr. Liu continues to serve as President and as a director of the

Company.

From March 2026 to October

2026, Ms. Pussinen served as Managing Director, Biotech Investments, of Sorbie Bornholm Ltd., an investment firm focused on micro- and

small-capitalization public companies, and since 2023 she has provided strategic and operational consulting services to life sciences

companies and investors. From August 2023 to August 2024, she was Chief Executive Officer and a director of Sernova Corp., a clinical-stage

cell therapy company, and from January 2021 to November 2022 she was Chief Technical Officer of Spark Therapeutics, Inc., a gene therapy

company and a member of the Roche Group, where she was responsible for technical development, manufacturing and operations.

Other than as described below,

there are no arrangements or understandings between Ms. Pussinen and any other person pursuant to which she was selected as an officer

or director. Ms. Pussinen has no family relationship with any director or executive officer of the Company, and there are no transactions

involving Ms. Pussinen that would require disclosure under Item 404(a) of Regulation S-K.

In connection with her appointment,

the Company entered into an Employment Agreement with Ms. Pussinen, dated as of October 25, 2026 (the “Employment Agreement”),

which was approved by the Compensation Committee of the Board (the “Compensation Committee”) and the Board and pursuant to

which the Company agreed to appoint Ms. Pussinen as Chairperson of the Board and to nominate her for election as a director during her

employment. The Employment Agreement provides for an annual base salary of $250,000, which will increase automatically to $400,000, $450,000

and $525,000 when cumulative qualifying funding received by the Company after October 25, 2026 first exceeds $35.0 million, $55.0 million

and $75.0 million, respectively, and an annual cash bonus with a target of 60% of base salary for 2026 and, thereafter, a target of 55%

to 70% of base salary as set by the Compensation Committee. If Ms. Pussinen’s employment is terminated by the Company without cause

or by her for good reason (each as defined in the Employment Agreement), she will be entitled, subject to her execution of a release of

claims, to 12 months of base salary continuation, any earned but unpaid bonus for the prior year, a prorated target bonus for the year

of termination and up to 12 months of employer-paid COBRA premiums; if such a termination occurs within 90 days before or 12 months after

a change in control, she will instead receive 12 months of base salary in a lump sum, any earned but unpaid bonus for the prior year,

her full target bonus for the year of termination, up to 12 months of employer-paid COBRA premiums and full acceleration of her unvested

equity awards.

1

The Employment Agreement also

provides for, and the Compensation Committee and the Board approved, the grant to Ms. Pussinen under the Company’s 2023 Omnibus

Incentive Plan of an option to purchase 1,000,000 shares of the Company’s common stock, to be granted on the second business day

following the filing of this Current Report with an exercise price equal to the closing price of the common stock on The Nasdaq Stock

Market on the grant date. The option will have a ten-year term and will vest as to 25% of the shares on October 25, 2027 and as to the

remainder in 36 equal monthly installments thereafter, subject to Ms. Pussinen’s continued service and to the acceleration described

above. The Employment Agreement also provides for the indemnification of Ms. Pussinen to the fullest extent permitted by Delaware law

and requires the Company to enter into its standard form of indemnification agreement with her. In addition, the Compensation Committee

and the Board approved the deferral of Ms. Pussinen’s base salary on the same terms as the deferral of the base salaries of Dr.

Liu and Mr. Xu described below.

The foregoing description

of the Employment Agreement is qualified in its entirety by reference to the Employment Agreement, which is filed as Exhibit 10.1 hereto

and incorporated herein by reference.

Also on October 25, 2026,

the Company entered into Amendment No. 1 to its Employment Agreement dated as of November 1, 2024 with Dr. Liu and Amendment No. 1 to

its Employment Agreement dated as of September 29, 2023 with Jiandong (Peter) Xu, the Company’s Chief Financial Officer (together,

the “Amendments”), each of which was approved by the Compensation Committee and the Board. The Amendments reflect Dr. Liu’s

position as President and Chief Scientific Officer, including his consent to the change in his position described above, and conform the

base salary, annual cash bonus, benefits and severance and change in control terms of Dr. Liu and Mr. Xu to those provided to Ms. Pussinen

under the Employment Agreement as described above, with the automatic base salary increases measured by reference to cumulative qualifying

funding received after October 25, 2026. The Amendments do not provide for any new equity awards. The Company continues to defer payment

of the base salaries of Dr. Liu and Mr. Xu, as adjusted by the Amendments, without interest, pending the completion of additional financing.

The foregoing description

of the Amendments is qualified in its entirety by reference to the Amendments, which are filed as Exhibits 10.2 and 10.3 hereto and incorporated

herein by reference.

Item

8.01 Other Events.

On October 25, 2026, the Board

adopted resolutions providing that the Board will not exercise its authority under Article V, Section A of the Company’s Second

Amended and Restated Certificate of Incorporation to leave any class of directors unoccupied and will fill any class that would otherwise

have no members, so that directors stand for election at each annual meeting of stockholders. Following Ms. Pussinen’s appointment

as a Class I director, each of the three classes of directors has at least one member. The Board also adopted a resolution proposing,

and declaring advisable, an amendment to Article V, Section A that would eliminate that authority and provide that the three classes of

directors be as nearly equal in number as possible, directed that the proposed amendment be submitted to stockholders for approval at

the Company’s 2027 annual meeting of stockholders, and resolved that, if the proposed amendment is not approved at that meeting,

the Board will submit it, or an amendment having substantially the same effect, for stockholder approval at each subsequent annual meeting

of stockholders until it is approved. The proposed amendment will be described in the Company’s proxy statement for the 2027 annual

meeting.

Item

9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1†

Employment Agreement, dated as of October 25, 2026, by and between Estrella Immunopharma, Inc. and Cynthia Pussinen.

10.2†

Amendment No. 1 to Employment Agreement, dated as of October 25, 2026, by and between Estrella Immunopharma, Inc. and Cheng Liu, Ph.D.

10.3†

Amendment No. 1 to Employment Agreement, dated as of October 25, 2026, by and between Estrella Immunopharma, Inc. and Jiandong (Peter) Xu.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

† Indicates a management contract or compensatory plan or arrangement.

2

SIGNATURE

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

ESTRELLA IMMUNOPHARMA, INC.

Date: October 29, 2026

By:

/s/ Peter Xu

Name:

Peter Xu

Title:

Chief Financial Officer

3

EX-10.1 — EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND CYNTHIA PUSSINEN

EX-10.1

Filename: ea031020901ex10-1.htm · Sequence: 2

Exhibit 10.1

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”),

dated as of October 25, 2026, is made by and between Estrella Immunopharma, Inc. a Delaware corporation (the “Company”), and

Cynthia Pussinen (“Executive”). This Agreement shall govern the employment relationship between Executive and the Company

from and after the Effective Date (as defined below).

WHEREAS, the Company desires to employ Executive

as its Chief Executive Officer and to be assured that the unique and expert services of Executive will be available to the Company and

that the confidential information and goodwill of the Company will be preserved for its exclusive benefit; and

WHEREAS, the Company desires to employ Executive

pursuant to the terms and conditions set forth in this Agreement, effective as of October 25, 2026 (such date on which this Agreement

becomes effective, the “Effective Date”), and Executive is willing and able to render such services and desires to do so on

the terms and conditions hereinafter set forth herein.

NOW, THEREFORE, in consideration of the above

recitals incorporated herein and the mutual covenants and promises contained herein and other good and valuable consideration, the receipt

and sufficiency of which are hereby expressly acknowledged, the parties agree as follows:

1. Retention and Duties.

(a) The Company hereby agrees

to engage and employ Executive for the Period of Employment (as defined in Section 2) on the terms and conditions expressly set forth

in this Agreement. Executive hereby accepts and agrees to such engagement and employment, on the terms and conditions expressly set forth

in this Agreement.

(b) During the Period of Employment,

Executive shall serve as Chief Executive Officer of the Company. Subject to applicable corporate law, fiduciary duties, stockholder election

requirements and Nasdaq rules, the Company shall take all appropriate corporate actions to appoint Executive as Chairperson of the board

of directors of the Company (the “Board”) effective on the Effective Date and to nominate Executive for reelection to the

Board during the Period of Employment. Executive shall report directly to the Board, with the duties, authority, budget oversight and

decision-making responsibilities customarily exercised by a public biotechnology company chief executive officer and chairperson of the

board, subject to reserved Board matters. Executive’s principal work location shall be Connecticut, with remote/hybrid work permitted

and reasonable business travel to Emeryville and other locations as necessary. Executive shall not be required to relocate. All reasonable

Company travel expenses shall be reimbursed under Section 3(d).

(c) During the Period of Employment,

Executive shall (i) devote substantially all of Executive’s business time, energy and skill to the performance of Executive’s

duties for the Company, (ii) perform such duties in a faithful, effective and efficient manner, and (iii) hold no other employment; provided

that the foregoing shall not prevent Executive from continuing to participate in such charitable, civic, educational, professional, community

or industry affairs or being a member of the board of directors of other public or private companies, as disclosed to and approved in

writing by the Board (including those set forth on Exhibit B hereto), so long as such activities do not, either individually or in the

aggregate, materially interfere or conflict with Executive’s duties hereunder or result in a breach of any restrictive covenant

obligation of Executive. Executive agrees to perform Executive’s duties and responsibilities within and subject to the Company’s

general employment policies and practices, and such other reasonable policies, practices and restrictions as the Company shall from time

to time establish for its similarly situated executives.

(d) Executive hereby represents

to the Company that: (i) the execution and delivery of this Agreement and the performance by Executive of Executive’s duties hereunder

do not and shall not constitute a breach of, conflict with, or otherwise contravene or cause a default under, the terms of any other agreement

or policy to which Executive is a party or otherwise bound or any judgment, order or decree to which Executive is subject; (ii) Executive

has no information (including, without limitation, confidential information and trade secrets) relating to any other person or entity

that would prevent Executive under the terms of any other agreement or arrangement from entering into this Agreement or carrying out Executive’s

duties hereunder, or would give rise to a violation of such other agreement or arrangement by virtue of Executive entering into this Agreement

and carrying out Executive’s duties hereunder; (iii) Executive is not bound by any employment, consulting, non-competition, confidentiality,

trade secret or similar agreement (other than this Agreement) with any other person or entity that would prevent Executive under the terms

of any other agreement or arrangement from entering into this Agreement or carrying out Executive’s duties hereunder, or would give

rise to a violation of such other agreement or arrangement by virtue of Executive entering into this Agreement and carrying out Executive’s

duties hereunder; and (iv) Executive understands the Company will rely upon the accuracy and truth of the representations and warranties

of Executive set forth herein.

2. Period of Employment. The “Period

of Employment” shall be the period commencing on the Effective Date and continuing until Executive’s employment with the Company

terminates pursuant to Section 5. Notwithstanding anything to the contrary in this Agreement, Executive’s employment with the Company

shall be “at will.”

3. Compensation and Reimbursement of Expenses.

(a) Base Salary. Executive’s

starting annual Base Salary shall be US$250,000, payable on the Company’s normal payroll schedule. Base Salary shall increase automatically,

without further Board or Compensation Committee action, to $400,000 when Cumulative Qualifying Funding first exceeds $35,000,000; to $450,000

when it first exceeds $55,000,000; and to $525,000 when it first exceeds $75,000,000. “Cumulative Qualifying Funding” means

the aggregate cash actually received by the Company or its controlled subsidiaries on or after the Effective Date through equity investments

(including PIPEs), strategic investments, grants, licensing or partnership upfront payments and milestone payments, acquisition-related

net cash proceeds, acquired unrestricted cash that becomes available to the Company, and other business-development financing transactions.

Amounts shall count once only, net of amounts returned, refunded or cancelled; announced deal values, contingent unpaid consideration

and undrawn credit facilities do not count until received. Separate tranches count when received; multiple qualifying transactions aggregate.

The increased Base Salary becomes effective on the date the applicable threshold is exceeded and any retroactive payroll difference shall

be paid in the next practicable payroll, no later than 30 days thereafter. Once attained, any Base Salary level is permanent and shall

never be reduced, including as part of an across-the-board reduction, due to later expenditures or declines in cash balance, or otherwise,

without Executive’s express written consent. The Board may increase but shall not decrease Base Salary. The Company shall maintain

and provide Executive on reasonable request an accounting of qualifying receipts. The parties acknowledge that a portion of Base Salary

constitutes consideration for the enforceable covenants under Section 6.

2

(b) Annual Cash Bonus. Executive

shall have an annual target cash bonus opportunity (the “Annual Bonus”) equal to sixty percent (60%) of Base Salary for the

first fiscal year and thereafter no less than fifty-five percent (55%) and up to seventy percent (70%) of Base Salary, with the annual

target percentage established in writing by the Compensation Committee of the Board (the “Compensation Committee”) no later

than 60 days after the start of each fiscal year; absent timely written adjustment, the target shall remain 60%, and no decrease below

a prior approved higher target may occur without Executive’s written consent. The Compensation Committee shall establish objective,

reasonably achievable financial, clinical, operational, strategic-transaction and individual performance objectives after consultation

with Executive. Achievement above target may merit payment above target pursuant to an approved bonus program. Bonuses shall be calculated

using Base Salary actually earned during the fiscal year, accounting for salary accelerators, and shall be paid no later than March 15

of the following year, subject to legally required deferral provisions. Executive shall receive a prorated Annual Bonus for a partial

initial year and, on a termination without Cause or resignation for Good Reason, a prorated target Annual Bonus for the termination year,

payable under Section 5(c). Any Annual Bonus for a completed performance year shall remain payable notwithstanding separation before the

ordinary payment date, except termination for Cause.

(c) Incentive Equity. During

the Period of Employment, Executive will be eligible to receive an annual grant of incentive equity awards pursuant to any plans or arrangements

the Company may have in effect from time to time. The Compensation Committee of the Board will determine in its discretion the terms of

any equity award in accordance with the terms of the Company’s applicable incentive plan or arrangement that may be in effect from

time to time.

(d) Reimbursement of Business Expenses.

The Company shall reimburse reasonable, documented expenses incurred for Company business, including air and ground travel, appropriate

lodging, communications, professional memberships, investor/partner meetings, and reasonable meals and entertainment. Executive may book

reasonable executive-level accommodations consistent with Company resources and business needs. No relocation shall be required. Reimbursement

shall be made within 30 days after submission of documentation (or earlier when required by law); advance approval rules must be reasonable,

disclosed in writing and not applied retroactively.

(e) Clawback Policy. To the extent

required by applicable law or regulation, any applicable stock exchange listing standards or any clawback policy adopted by the Company

pursuant to any such law, regulation or stock exchange listing standards (including, without limitation, the Company’s compensation

recovery policy adopted pursuant to Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule

10D-1 thereunder and Nasdaq Listing Rule 5608, as in effect from time to time), or to comport with good corporate governance practices,

the Annual Bonus and any other incentive compensation granted to Executive (whether pursuant to this Employment Agreement or otherwise,

and including the Initial Option (as defined below)) shall be subject to the provisions of any applicable clawback policies or procedures,

which may provide for forfeiture and/or recoupment of such amounts paid or payable under this Employment Agreement or otherwise, including

incentive equity awards granted to Executive.

3

(f) Initial Option Grant.

(i) Grant. Subject to approval

by the Compensation Committee (which, for purposes of the exemption provided by Rule 16b-3 under the Exchange Act, shall consist solely

of “non-employee directors” within the meaning of such rule), the Company shall grant to Executive an option to purchase one

million (1,000,000) shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (the “Initial

Option”), under the Company’s 2023 Omnibus Incentive Plan (as amended from time to time, the “Plan”). The Initial

Option shall be granted on the date specified by the Compensation Committee in approving the grant, which is expected to occur on or as

promptly as practicable following the Effective Date (the “Grant Date”); provided that the Compensation Committee may determine

the Grant Date in accordance with the Company’s equity award grant practices, including so that the Grant Date does not fall within

the period beginning four (4) business days before and ending one (1) business day after the filing of a periodic report on Form 10-Q

or Form 10-K, or the filing or furnishing of a current report on Form 8-K that discloses material nonpublic information. Executive acknowledges

that this Agreement does not itself grant any option or other equity award, and that Executive shall have no rights with respect to the

Initial Option unless and until it is approved by the Compensation Committee and evidenced by a written award agreement executed by the

Company and Executive.

(ii) Exercise Price. The Initial

Option shall have a per-share exercise price equal to one hundred percent (100%) of the Fair Market Value (as defined in the Plan) of

a share of Common Stock on the Grant Date, which, for so long as the Common Stock is listed on The Nasdaq Stock Market, shall be the closing

sales price of a share of Common Stock as reported on such exchange on the Grant Date; provided, that if Executive owns (or is deemed

to own under Section 424(d) of the Code (as defined below)) more than ten percent (10%) of the total combined voting power of all classes

of stock of the Company on the Grant Date, the exercise price of any portion of the Initial Option intended to qualify as an incentive

stock option shall be not less than one hundred ten percent (110%) of such Fair Market Value. In no event shall the exercise price be

determined by reference to any date before the Grant Date.

(iii) Type of Option. The Initial

Option shall be designated as an “incentive stock option” within the meaning of Section 422 of the Code to the maximum extent

permitted by Section 422 of the Code (including the $100,000 limitation of Section 422(d) of the Code) and by the incentive stock option

share limit of the Plan, and the remainder of the Initial Option shall be a nonqualified stock option. The Company makes no representation

or warranty that any portion of the Initial Option will qualify as an incentive stock option.

(iv) Vesting. The Initial Option

shall vest and become exercisable as follows, subject to Executive’s continuous service with the Company through each applicable

vesting date: twenty-five percent (25%) of the shares subject to the Initial Option shall vest on the first (1st) anniversary of the Effective

Date (the “Vesting Commencement Date” being the Effective Date), and the remaining seventy-five percent (75%) of the shares

subject to the Initial Option shall vest in thirty-six (36) substantially equal monthly installments on the corresponding day of each

month thereafter, such that the Initial Option shall be fully vested on the fourth (4th) anniversary of the Effective Date. The Initial

Option shall be eligible for accelerated vesting as provided in Section 5(c)(iii) of this Agreement.

4

(v) Term; Post-Termination Exercise.

The Initial Option shall have a maximum term of ten (10) years from the Grant Date (or five (5) years from the Grant Date with respect

to any portion of the Initial Option that is an incentive stock option granted to a holder of more than ten percent (10%) of the total

combined voting power of the Company, if applicable), subject to earlier termination as provided in the Plan and the applicable award

agreement. Except as otherwise provided in Section 3(f)(iv) and Section 5(c)(iii) of this Agreement, any portion of the Initial Option

that is unvested as of the Separation Date shall be forfeited without consideration, and any vested portion shall remain exercisable for

the period following the Separation Date set forth in the Plan and the applicable award agreement.

(vi) Governing Documents. The Initial

Option shall be subject in all respects to the terms and conditions of the Plan and the Company’s standard form of stock option

award agreement, including the provisions of the Plan relating to adjustments upon changes in capitalization and the treatment of awards

in connection with a Change in Control. In the event of any conflict between this Section 3(f) and the Plan, the Plan shall control; provided,

that the accelerated vesting provided under Section 3(f)(iv) and Section 5(c)(iii) of this Agreement shall apply to the Initial Option

to the extent permitted by the Plan.

(vii) Securities Law and Company Policy

Compliance. The Company intends that the shares of Common Stock issuable upon exercise of the Initial Option will be registered under

the Securities Act of 1933, as amended, on a registration statement on Form S-8. Executive acknowledges that, as an executive officer

of the Company, Executive will be subject to (A) the reporting requirements and short-swing profit provisions of Section 16 of the Exchange

Act, (B) the Company’s insider trading policy, including any applicable blackout periods and pre-clearance procedures, as in effect

from time to time, and (C) any applicable restrictions on resale under Rule 144 under the Securities Act of 1933, as amended. Executive

agrees to provide the Company, on a timely basis, with such information as the Company may reasonably request to enable the Company to

assist Executive with Executive’s filings under Section 16 of the Exchange Act and to comply with the Company’s disclosure

obligations under applicable securities laws.

(viii) Tax Matters. The Initial

Option is intended to be exempt from Section 409A as a stock right with an exercise price not less than the fair market value of the underlying

stock on the Grant Date, and shall be interpreted and administered accordingly. Any exercise of the Initial Option and any disposition

of the shares acquired upon exercise shall be subject to applicable tax withholding in accordance with Section 8 of this Agreement and

the Plan. Executive acknowledges that Executive has been advised to consult with Executive’s own tax advisor regarding the tax consequences

of the Initial Option.

5

4. Employee Benefits.

(a) Company Employee Benefit Plans.

During the Period of Employment, Executive and Executive’s eligible dependents shall be eligible to participate in all health, dental,

vision, life, disability and retirement programs available to similarly situated executives of the Company, subject to applicable plan

terms, and to receive benefits no less favorable than those afforded to other senior officers of the Company. The Company may modify generally

applicable plans in compliance with law, but shall not selectively reduce Executive’s contractual compensation or negotiated rights.

The Company shall provide a current written summary of available coverage, premium sharing and eligibility prior to the Effective Date.

(b) Vacation and Other Leave.

During the Period of Employment, Executive shall be eligible to receive paid vacation in accordance with and subject to the Company’s

vacation policies in effect from time to time. Vacations are to be taken at times mutually agreeable to the Company and the Executive.

5. Termination of Employment.

(a) Termination by the Company; Termination

Due to Death. Executive’s employment with the Company and the Period of Employment may be terminated by the Company immediately

upon notice to Executive for an involuntary termination of employment for Cause (as defined below), without Cause or due to Executive’s

Disability (as defined below). Executive’s employment with the Company, and the Period of Employment, shall automatically terminate

upon Executive’s death.

(b) Termination by Executive.

Executive’s employment with the Company, and the Period of Employment, may be terminated by Executive for any reason with no less

than ninety (90) days’ advance written notice to the Company. Upon Executive’s resignation, Executive shall cooperate as reasonably

requested by the Board to effectuate an orderly transition.

(c) Benefits upon Termination.

If Executive’s employment with the Company is terminated during the Period of Employment for any reason by the Company or by Executive,

the Company shall have no further obligation to make or provide to Executive, and Executive shall have no further right to receive or

obtain from the Company, any payments or benefits except as follows:

(i) The Company shall pay Executive

(or, in the event of Executive’s death, Executive’s estate) any Accrued Obligations (as defined below) within the thirty (30)

day period following the date Executive’s employment terminates (the “Separation Date”), or such earlier date as may

be required by applicable law, and Executive shall receive any vested accrued benefits for which Executive remains eligible under the

Company’s employee welfare benefit and retirement plans, payable according to the terms of such plans. Executive and Executive’s

eligible dependents shall be eligible for continued coverage under the group medical care plans provided to employees of the Company in

accordance with the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) and/or state law, subject

to the terms and conditions thereof, and at Executive’s own expense.

6

(ii) If, during the Period of Employment,

Executive’s employment with the Company ends as a result of an involuntary termination by the Company without Cause or Executive’s

resignation for Good Reason other than in connection with a Change in Control, then, in addition to the amounts payable under Section

5(c)(i), subject to Executive’s timely execution and non-revocation of the general release described in Section 5(d) (the “General

Release”) and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve (12) months of Base

Salary (at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good Reason triggered

by a reduction in Base Salary, the rate in effect prior to the reduction), payable in substantially equal installments on each of the

Company’s regular payroll payment dates during the twelve (12) months following the Separation Date; (B) to the extent unpaid as

of the Separation Date, the Annual Bonus for the fiscal year immediately preceding the year in which the Separation Date occurs, payable

at the time such Annual Bonus would otherwise have been paid under Section 3(b); (C) a prorated target Annual Bonus for the fiscal year

in which the Separation Date occurs, payable in a lump sum on the first regular payroll date following the effectiveness of the General

Release; and (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums

for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon

Executive’s eligibility for substantially comparable employer-sponsored coverage ((A) through (D) collectively, the “Severance

Payments”); provided, that no installment or portion of the Severance Payments shall be payable or paid until the expiration of

the applicable revocation period for the General Release. Notwithstanding anything herein to the contrary, if any Severance Payment is

“nonqualified deferred compensation” within the meaning of Section 409A and the period to consider and, if applicable, revoke

the General Release plus the first regular payroll date thereafter spans two calendar years, then no portion of the Severance Payments

shall be paid until the Company’s first payroll payment date in the second calendar year, and any amount not paid prior to such

date due to such restriction shall be paid in a lump sum along with the installment scheduled to be paid on that date.

(iii) If Executive’s employment

is terminated by the Company without Cause or by Executive for Good Reason within the ninety (90) days prior to a Change in Control or

within the twelve (12) months following a Change in Control, then, in addition to the amounts payable under Section 5(c)(i) but in lieu

of the Severance Payments payable under Section 5(c)(ii), subject to Executive’s timely execution and non-revocation of the General

Release and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve (12) months of Base Salary

(at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good Reason triggered by a reduction

in Base Salary, the rate in effect prior to the reduction), payable in a lump sum on the first regular payroll date following the effectiveness

of the General Release; (B) to the extent unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding

the year in which the Separation Date occurs, payable at the time such Annual Bonus would otherwise have been paid under Section 3(b);

(C) a lump-sum payment, payable on the first regular payroll date following the effectiveness of the General Release, equal to one hundred

percent (100%) of Executive’s target Annual Bonus for the fiscal year in which the Separation Date occurs (which amount shall not

be prorated); (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums

for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon

Executive’s eligibility for substantially comparable employer-sponsored coverage; and (E) acceleration of one hundred percent (100%)

of Executive’s outstanding unvested equity awards as of the Separation Date; provided, however, that if an outstanding equity award

is to vest and/or the amount of the equity award to vest is to be determined based on the achievement of performance criteria, then the

equity award will vest as to one hundred percent (100%) of the amount of the equity award assuming the performance criteria had been achieved

at target levels for the relevant performance period(s), unless otherwise provided in the applicable award agreement ((A) through (E)

collectively, the “Change in Control Severance Payments”). For a qualifying termination occurring prior to a Change in Control,

any equity award that was forfeited on the Separation Date shall be treated as having remained outstanding through the closing of the

Change in Control for purposes of this clause (E), to the extent permitted by the applicable plan.

7

(iv) A material, finally determined

breach by Executive of enforceable continuing obligations under Section 6, after written notice and a reasonable opportunity to cure where

curable, may permit only prospective suspension of amounts not legally protected, subject to applicable law and judicial review. Accrued

wages, earned bonuses, vested equity and indemnification rights shall not be forfeited solely by allegation of breach.

(d) General Release. This Section

5(d) shall apply notwithstanding anything else in this Agreement to the contrary. As a condition precedent to any Company obligation to

Executive pursuant to Section 5(c)(ii) or 5(c)(iii), as applicable, Executive shall provide the Company with a valid, executed General

Release in a customary, standard form of the Company, which shall not contain any more onerous restrictive covenants than those contained

herein, and not revoke such General Release prior to the expiration of any revocation rights afforded to Executive by applicable law.

The Company shall provide Executive with the General Release prior to the Separation Date, and Executive must deliver the executed General

Release to the Company within twenty-one (21) days (or, if greater, the minimum period required by applicable law) after the Separation

Date, failing which Executive will forfeit all rights to the payments and benefits set forth in Section 5(c)(ii) or 5(c)(iii) (as applicable).

(e) Exclusive Remedy. Section

5(c) provides the parties’ agreed contractual severance treatment but shall not preclude Executive from enforcing this Agreement,

exercising vested equity rights, recovering accrued salary or earned bonuses, asserting indemnification or advancement rights, seeking

relief for discrimination, retaliation or other statutory violations, or pursuing benefits expressly protected by applicable law. Nothing

herein requires waiver of claims that cannot legally be waived.

(f) Certain Defined Terms. As

used in this Agreement:

(i) “Accrued Obligations”

means (A) any Base Salary that had accrued but had not been paid (including any amount for accrued and unused vacation time payable in

accordance with the Company’s vacation policy then in effect or applicable law) on or before the Separation Date, (B) any reimbursement

due to Executive pursuant to Section 3(d) for expenses incurred by Executive on or before the Separation Date and (C) any other vested

benefits or vested amounts due and owed to Executive under the terms of any plan, program or arrangement of the Company.

8

(ii) “Cause” means

(A) final conviction of or guilty/nolo contendere plea to a felony involving dishonesty or material harm to the Company or its affiliates

or subsidiaries (the “Company Group” and each a “Company Group Member”); (B) willful fraud, theft or embezzlement

against the Company Group; (C) willful and material failure to perform lawful duties as Chief Executive Officer after a specific written

demand identifying the deficiency and at least thirty (30) days to cure where curable; (D) willful and material breach of this Agreement

or a material written Company policy applicable to senior executives, after thirty (30) days’ written notice and opportunity to

cure where curable; or (E) willful misconduct or gross negligence resulting in demonstrable material harm to the Company Group. An act

is not “willful” if undertaken in good faith with a reasonable belief that it served the Company’s interests. No termination

for Cause shall occur without written particulars and a reasonable opportunity for Executive and counsel to respond to disinterested Board

members; Executive shall recuse herself from the Board’s determination. Cause shall not include mere business disagreement, an unsuccessful

good- faith strategic decision, or failure to meet results in the absence of misconduct. Notwithstanding the foregoing, no Cause shall

exist unless the Company has provided the Executive written notice detailing the event constituting Cause and, to the extent the event

is reasonably susceptible to cure, the Executive does not cure such event within thirty (30) days of the receipt of such notice.

(iii) “Change in Control”

shall have the meaning as defined (or as the analogous term is defined) in the Company’s incentive plan(s) under which equity awards

are or have been granted to Executive from time to time.

(iv) “Disability” means

a physical or mental impairment that renders Executive unable to perform the essential functions of Executive’s employment with

the Company, even with reasonable accommodation that does not impose an undue hardship on the Company, for ninety (90) days (whether or

not continuous) during any period of one-hundred eighty (180) consecutive days, unless a longer period is required by federal or state

law, in which case that longer period would apply.

(v) “Good Reason” means,

without Executive’s prior written consent: (A) any reduction in Base Salary (except for a decrease of not more than ten percent

(10%) in connection with any across-the-board reduction impacting substantially all executives of the Company); (B) a material decrease

in the target Annual Bonus opportunity; (C) material diminution of Executive’s responsibilities, authority or status as Chief Executive

Officer; (D) required relocation of Executive’s principal work location outside Connecticut or removal of the agreed Connecticut-based

remote/hybrid arrangement; (E) material breach of this Agreement by the Company, including repeated failure to pay amounts when due; or

(F) failure of a successor to assume this Agreement. Executive shall notify the Company within ninety (90) days after learning of the

condition, the Company shall have thirty (30) days to cure, and Executive shall terminate within ninety (90) days following expiration

of the cure period if uncured.

(vi) “Section 409A”

means Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations, rules and other guidance

promulgated thereunder.

9

(g) Officer/Board/Committee Resignations.

Upon termination of employment, Executive shall resign from Company officer positions, but a resignation from the Board or the position

of Chairperson of the Board shall be subject to applicable law, the Company’s governing documents and any separately negotiated

Board transition arrangement. No deemed resignation shall deprive Executive of rights arising from a Company-initiated removal that constitutes

Good Reason, or of accrued equity, indemnification or advancement rights.

(h) Section 409A.

(i) It is the intention of the

parties that Executive’s performance of the services under this Agreement and payments to Executive under this Agreement shall not

implicate Section 409A. In the event that Executive’s performance of the services or any payment due to the Executive under this

Agreement would subject Executive to the additional tax and interest imposed by Section 409A, or any interest or penalties with respect

to such additional tax, the Company shall modify this Agreement to make it compliant with Section 409A and maintain the value of the payments

and benefits under the Agreement. In no event, however, shall the Company be liable for any tax, interest or penalty imposed on Executive

under Section 409A or any damages for failing to comply with Section 409A.

(ii) If at the time of the Executive’s

termination of employment, the Executive is a “specified employee,” under Section 409A, any and all amounts payable under

this Agreement on account of such termination of employment that would (but for this provision) be payable within six (6) months following

the date of termination, shall instead be paid on the next business day following the expiration of such six (6) month period or, if earlier,

the date of the Executive’s death; except (A) to the extent of amounts that do not constitute a deferral of compensation within

the meaning of Section 409A; (B) benefits which qualify as excepted welfare benefits pursuant to Section 409A-1(a)(5); or (C) other amounts

or benefits that are not subject to the requirements of Section 409A. Each payment made under this Agreement shall be treated as a separate

payment and the right to a series of installment payments under this Agreement is to be treated as a right to a series of separate payments.

(iii) Any reimbursement payment

or in-kind benefit due to Executive pursuant to Section 3(d), to the extent that such reimbursements or in-kind benefits are taxable to

Executive, shall be paid on or before the last day of Executive’s taxable year following the taxable year in which the related expense

was incurred. Executive agrees to provide prompt notice to the Company of any such expenses (and any other documentation that the Company

may reasonably require to substantiate such expenses) in order to facilitate the Company’s timely reimbursement of the same. Reimbursements

and in-kind benefits pursuant to Section 3(d) are not subject to liquidation or exchange for another benefit and the amount of such benefits

that Executive receives in one taxable year shall not affect the amount of such reimbursements or benefits that Executive receives in

any other taxable year.

(iv) For purposes of Section 409A,

Executive’s right to receive any installment payments hereunder shall be treated as a right to receive a series of separate and

distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g., payment

shall be made within thirty (30) days following the date of termination), the actual date of payment within the specified period shall

be within the sole discretion of the Company.

10

6. Restrictive Covenants.

(a) Non-Disclosure and Non-Use

of Confidential Information.

(i) Executive agrees that during

the Period of Employment and following the termination thereof for any reason, the Executive shall not, and shall cause his affiliates

and representatives not to, disclose to any individual or natural person, partnership (including a limited liability partnership), corporation,

limited liability company, association, joint stock company, trust, joint venture, unincorporated organization or governmental authority

(each, a “Person”), except (i) to the Executive’s legal, financial, tax or accounting advisors, or (ii) as compelled

by law, any Confidential Information for any reason or purpose whatsoever, and the Executive shall not, and shall cause Executive’s

affiliates or representatives not to, make use of any of the Confidential Information for their own purposes or for the benefit of any

Person except any Company Group Member. In the event that Executive or any of Executive’s affiliates or representatives are compelled

by law to disclose any Confidential Information, the Executive shall promptly provide written notice to the Company of the request or

requirement so that the Company may seek (at the Company’s sole cost and expense) an appropriate protective order or waive compliance

with the provisions of this Section 6(a). If, in the absence of a protective order or the receipt of a waiver hereunder, the Executive

or any of the Executive’s affiliates or representatives are compelled by law to disclose any Confidential Information to any tribunal,

the Executive or the Executive’s affiliates, as applicable, may disclose the Confidential Information to the tribunal; provided,

that the Executive or the Executive’s affiliates, as applicable, shall use commercially reasonable efforts to obtain, at the request

and sole expense of the Company, an order or other assurance that confidential treatment shall be accorded to such portion of the Confidential

Information required to be disclosed as the Company shall designate.

(ii) For purposes of this Agreement,

“Confidential Information” shall mean any information of a confidential or proprietary nature concerning the business or affairs

of the Company Group; provided however, “Confidential Information” shall not include information which (i) is or becomes generally

available to the public other than as a result of disclosure by Executive or any of the Executive’s affiliates to the receiving

party in violation of this Agreement or (ii) becomes available to the Executive or any of the Executive’s affiliates on a non-confidential

basis from a source other than any Company Group Member, so long as such source is not known by the Executive to be bound by a confidentiality

agreement with any of the foregoing prohibiting such disclosure.

(iii) For the avoidance of doubt,

this Section 6(a) does not prohibit or restrict Executive (or Executive’s attorney) from responding to any inquiry about this Agreement

or its underlying facts and circumstances by the Securities and Exchange Commission, the Financial Industry Regulatory Authority, or any

other self-regulatory organization or governmental authority, or making other disclosures that are protected under the whistleblower provisions

of federal law or regulation. Executive understands and acknowledges that Executive does not need the prior authorization of the Company

to make any such reports or disclosures and that Executive is not required to notify the Company that Executive has made such reports

or disclosures.

11

(iv) Notwithstanding anything in

this Section 6(a) or elsewhere in this Agreement to the contrary, Executive understands that Executive may, pursuant to the U.S. Defend

Trade Secrets Act of 2016 (“DTSA”), without informing the Company prior to any such disclosure, disclose Confidential Information

(A) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, solely for the

purpose of reporting or investigating a suspected violation of law or (B) in a complaint or other document filed in a lawsuit or other

proceeding, if such filing is made under seal. Additionally, without informing the Company prior to any such disclosure, if Executive

files a lawsuit against the Company for retaliation for reporting a suspected violation of law, Executive may, pursuant to the DTSA, disclose

Confidential Information to Executive’s attorney and use the Confidential Information in the court proceeding or arbitration, provided

that Executive files any document containing the Confidential Information under seal and does not otherwise disclose the Confidential

Information, except pursuant to court order. Without prior authorization of the Company, however, the Company does not authorize Executive

to disclose to any third party (including any government official or any attorney Executive may retain) any communications that are covered

by the Company’s attorney-client privilege.

(b) Intellectual Property Rights.

(i) Executive hereby assigns, transfers,

and conveys to the Company all of Executive’s right, title and interest in and to all Work Product (as defined below). Executive

agrees that all Work Product belongs in all instances to the Company. Executive will promptly disclose such Work Product to the Company

and perform all actions reasonably requested by the Company (whether during or after the Period of Employment) to establish and confirm

the Company’s ownership of such Work Product (including, without limitation, the execution and delivery of assignments, consents,

powers of attorney, and other instruments) and to provide reasonable assistance to the Company (whether during or after the Period of

Employment) in connection with the prosecution of any applications for patents, trademarks, trade names, service marks or reissues thereof

or in the prosecution or defense of interferences relating to any Work Product. Executive recognizes and agrees that the Work Product,

to the extent copyrightable, constitutes works for hire under the copyright laws of the United States.

(ii) For purposes of this Agreement,

“Work Product” means all inventions, innovations, improvements, technical information, systems, software developments, methods,

designs, analyses, drawings, reports, service marks, trademarks, trade names, trade dress, logos and all similar or related information

(whether patentable or unpatentable) which relates to the actual business, operations, research and development, or existing or future

products or services of the Company Group and which are conceived, developed, or made by Executive (whether or not during usual business

hours and whether or not alone or in conjunction with any other person) during the Period of Employment together with all patent applications,

letters patent, trademark, trade name, and service mark applications or registrations, copyrights and reissues thereof that may be granted

for or upon any of the foregoing. Notwithstanding the foregoing, “Work Product” shall not include the patents and other assets

set forth on Exhibit A hereto. Executive hereby represents and warrants that the patents and other assets owned by Executive set forth

on Exhibit A are not related in any way to the Company Group, except as stated therein.

12

(c) Non-Solicitation and Non-Interference.

During the Period of Employment Executive will not, and will cause Executive’s affiliates not to use confidential information to,

directly or indirectly through any other Person (whether as an officer, manager, director, employee, partner, consultant, holder of equity

or debt investment, lender or any other manner or capacity): (i) directly or indirectly contact, induce or solicit (or assist any Person

to contact, induce or solicit) for employment any person who is, or within the preceding twelve (12) months was, an executive employed

by a Company Group Member; or (ii) induce or attempt to induce any customer, supplier, or licensee of the Company Group within the preceding

twelve (12) months to cease doing business with the Company Group or in any way interfere with the relationship between the Company Group

and any such customer, supplier, or licensee.

(d) Mutual Non-Disparagement.

During and after the Period of Employment, Executive shall not knowingly make materially false statements of fact intended to harm the

Company or its officers or directors, and the Company shall instruct its directors and senior executive officers not to knowingly make

materially false statements of fact intended to harm Executive. This provision does not restrict truthful testimony, good-faith regulatory

reports, legal claims, lawful disclosures, protected concerted activity, statements to professional advisers or other speech protected

by law.

7. Acknowledgment and Enforcement of Covenants.

(a) Acknowledgment. Executive

acknowledges that Executive has become familiar, or will become familiar, with the Company Group Members’ trade secrets and with

other Confidential Information concerning the Company Group Members and their respective predecessors, successors, customers, and suppliers,

and that Executive’s services are of special, unique, and extraordinary value to the Company. Executive acknowledges and agrees

that the Company would not enter into this Agreement, providing for compensation and other benefits to Executive on the terms and conditions

set forth herein, but for Executive’s agreements herein (including those set forth in Section 6). Furthermore, Executive acknowledges

and agrees that the Company will be providing Executive with additional special knowledge after the Effective Date, with such special

knowledge to include additional Confidential Information and trade secrets. Executive agrees that the covenants set forth in Section 6

(collectively, the “Restrictive Covenants”) are reasonable and necessary to protect the Company Group’s trade secrets

and other Confidential Information, proprietary information, goodwill, stable workforce, and customer relations.

(b) Representations. Executive

acknowledges the legitimate need to protect the Company Group’s Confidential Information and trade secrets, but makes no advance

waiver of any statutory protections or right to challenge an unlawful, unreasonable or unenforceable restrictive covenant. The parties

intend enforcement only to the extent permitted under applicable law, including California law where applicable.

13

(c) Enforcement. Executive acknowledges

and agrees that money damages would not be an adequate remedy for any breach or threatened breach of the provisions of the Restrictive

Covenants and that the Company or any of its successors or assigns shall, in addition to any other rights and remedies existing in their

favor, be entitled to specific performance, injunctive and/or other relief from any court of competent jurisdiction in order to enforce

or prevent any violations of the Restrictive Covenants (including the extension of the restricted periods set forth in Section 6 by a

period equal to the length of any legal proceeding, arbitration, or other action necessary to stop such violation), provided, that Executive

is found to have been in violation of the Restrictive Covenants by a court of competent jurisdiction. Any injunction shall be available

without the posting of any bond or other security. In the event of an alleged breach or violation by Executive of any Restrictive Covenant,

the restricted period will be tolled for the Executive until such alleged breach or violation is resolved; provided, that if Executive

is found to have not violated the Restrictive Covenants, then the restricted period will not be deemed to have been tolled.

(d) Severability. If a court

of competent jurisdiction determines any Restrictive Covenant unenforceable, the court may enforce any lawful severable portion to the

extent permitted by applicable law, without enlarging the covenant. Executive retains the right to contest interpretation or enforceability

and to assert all lawful defenses. No provision shall require Executive to waive statutory rights or prevent lawful professional activity.

8. Withholding Taxes/Authorized Deductions.

Notwithstanding anything herein to the contrary, the Company may withhold (or cause to be withheld) from any amounts otherwise due or

payable under or pursuant to this Agreement such federal, state and local income, social security, employment or other taxes as may be

required to be withheld pursuant to any applicable law or regulation, and make such deductions as may be applicable pursuant to the Company’s

policies and employee benefit plans.

9. Cooperation. During and after the Period

of Employment, Executive shall cooperate fully with any investigation or inquiry by the Company, or any governmental or regulatory agency

or body concerning the Company or any other member of the Company, provided that the Company shall reimburse Executive’s reasonable

expenses incurred in providing such cooperation (including, without limitation, attorneys’ fees and lodging and meals) subject to

Executive’s delivery of written notice to the Company prior to the time such expenses are incurred.

10. Governing Law. This Agreement will

be governed by and construed in accordance with the laws of the State of California without giving effect to any choice or conflict of

law provision or rule (whether of the State of California or any other jurisdiction) that would cause the application of the laws of any

jurisdiction other than the State of California.

11. Consent to Jurisdiction. Subject to

mandatory statutory venue and jurisdiction rules, the parties consent to the state and federal courts located in California or Connecticut

for claims arising from this Agreement, at Executive’s election for claims she brings, and waive objections to personal jurisdiction

where lawful. Either party may seek provisional equitable relief in an otherwise competent court, without waiving available defenses or

statutory rights. Service of process shall comply with applicable law. Nothing herein limits a right to pursue a claim before an administrative

agency.

12. Waiver of Jury Trial. Each of the parties

hereto hereby irrevocably waives all right to trial by jury in any action, proceeding or counterclaim arising out of or relating to this

Agreement.

14

13. Severability. It is the desire and

intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible under the laws and public

policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular provision of this Agreement shall

be adjudicated by a court of competent jurisdiction to be invalid, prohibited or unenforceable under applicable law, such provision, as

to such jurisdiction, shall be ineffective without invalidating the remaining provisions of this Agreement or affecting the validity or

enforceability of such provision in any other jurisdiction.

14. Indemnification. To the fullest extent

permitted by Delaware law and the Company’s governing documents, the Company shall indemnify Executive for actions taken in good

faith in her capacity as an officer, director and Chairperson of the Board, and shall advance reasonable defense expenses promptly upon

appropriate undertaking where legally required. Before or at commencement of the Period of Employment, the Company and Executive shall

enter into a separate written indemnification agreement no less favorable than those of other directors. The Company shall maintain commercially

reasonable directors’ and officers’ liability insurance covering Executive on terms no less favorable than other senior officers

and directors throughout service and, for claims relating to such service, appropriate run-off/tail coverage for at least six (6) years

following a Change in Control, subject to commercially reasonable availability and cost. Executive may use independent counsel at Company

expense when an actual material conflict warrants it, to the extent legally permitted. These obligations survive termination.

15. Entire Agreement; Amendment. This Agreement,

the award agreement(s) evidencing the Initial Option and any other equity awards, the separate indemnification agreement and the completed

Exhibits A and B hereto embody the entire agreement of the parties hereto respecting the matters within their scope and supersede all

prior agreements, whether written or oral, that directly or indirectly bear upon the subject matter hereof. This Agreement may not be

amended, modified or changed (in whole or in part), except by written agreement executed by Executive and a duly authorized officer of

the Company following any required approval of the Board or the Compensation Committee.

16. Waiver. No waiver of any provision

of this Agreement will constitute or be deemed to constitute a waiver of any other provision of this Agreement, nor will any such waiver

constitute a continuing wavier unless otherwise expressly provided.

17. Successors and Assigns. This Agreement

cannot be assigned by the Company without the prior written consent of Executive, other than (a) an assignment to an affiliate of the

Company made as part of an internal reorganization applicable to employees of the Company generally or (b) to any successor or assign

(whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of

the Company, and shall be binding and inure to the benefit of the Company, its successors and any permitted assigns. No right, obligation

or duty of this Agreement may be assigned by Executive without the prior written consent of the Company.

15

18. Notices. Any notice provided for in

this Agreement must be in writing and must be either personally delivered, transmitted via email, mailed by first class mail (postage

prepaid and return receipt requested) or sent by reputable overnight courier service (charges prepaid) to the recipient at the address

below indicated or at such other address or to the attention of such other person as the recipient party has specified by prior written

notice to the sending party. Notices will be deemed to have been given hereunder and received when delivered personally, when received

if transmitted via telecopier or email, five days after deposit in the U.S. mail and one day after deposit with a reputable overnight

courier service.

If to the Company:

Estrella Immunopharma, Inc.

5858 Horton Street, Suite 370

Emeryville, CA 94608

Attention: Chief Financial Officer

If to Executive, to the address most recently

on file in the payroll records of the Company.

19. Section 280G. Payments under this Agreement

shall be made without regard to whether the deductibility of such payments (or any other payments to or for the benefit of the Executive)

would be limited or precluded by Section 280G of the Code without regard to whether such payments (or any other payments) would subject

the Executive to the federal excise tax levied on certain “excess parachute payments” under Section 4999 of the Code; provided,

that if the total of all payments to or for the benefit of the Executive (whether under this Agreement or otherwise), after reduction

for all state and federal taxes (including the tax described in Section 4999 of the Code, if applicable) with respect to such payments

(“Executive’s Total After-Tax Payments”), would be increased by the limitation or elimination of any payment under this

Agreement, amounts payable under this Agreement shall be reduced to the extent, and only to the extent, necessary to maximize the Executive’s

Total After-Tax Payments. The determination as to whether and to what extent payments under this Agreement are required to be reduced

in accordance with the preceding sentence shall be made at the Company’s expense by a nationally recognized accounting firm after

considering in good faith all available exemptions, including a fair valuation of reasonable compensation for services rendered by Executive

and a fair valuation for any post-employment covenants.

20. Legal Counsel; Mutual Drafting. Each

party recognizes that this is a legally binding contract and acknowledges and agrees that they have had the opportunity to consult with

legal counsel of their choice. Each party has cooperated in the drafting, negotiation and preparation of this Agreement. Hence, in any

construction to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter

of such language. Executive agrees and acknowledges that Executive has read and understands this Agreement, is entering into it freely

and voluntarily, and has been advised to seek counsel prior to entering into this Agreement and has had ample opportunity to do so.

21. Counterparts. This Agreement may be

executed in any number of counterparts, each of which shall be deemed an original as against any party whose signature appears thereon,

and all of which together shall constitute one and the same instrument.

[Signatures on Following Page]

16

IN WITNESS WHEREOF, the Company and Executive

have executed this Agreement as of the date first written above.

“COMPANY”

Estrella Immunopharma, Inc.

By:

/s/ Peter Xu

Name:

Peter Xu

Title:

Chief Financial Officer

“EXECUTIVE”

/s/ Cynthia Pussinen

Cynthia Pussinen

[Signature Page to Employment Agreement]

EXHIBIT A

EXCLUDED FROM WORK PRODUCT

☒ I have no inventions.

☐ The following is a complete list of all pre-existing intellectual

property and other assets to be excluded from the definition of Work Product relative to the subject matter of my employment with the

Company that have been created by me, alone or jointly with others, prior to the Effective Date, which might relate to the Company Group’s

present business:

☐ Additional sheets attached.

Executive:

/s/ Cynthia Pussinen

Date: October 25, 2026

Cynthia Pussinen

EXHIBIT B

PREAPPROVED OUTSIDE ACTIVITIES

The following directorships, advisory roles and

other professional commitments of Executive have been disclosed to and approved by the Board for purposes of Section 1(c) of the Agreement:

1. Board Director, Xelcis Bio

EX-10.2 — AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND CHENG LIU, PH.D

EX-10.2

Filename: ea031020901ex10-2.htm · Sequence: 3

Exhibit 10.2

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

This Amendment No. 1 to Employment Agreement (this

“Amendment”) is made and entered into effective as of October 25, 2026 (the “Amendment Effective Date”), by and

between Estrella Immunopharma, Inc., a Delaware corporation (the “Company”), and Cheng Liu (“Executive”). Capitalized

terms used but not defined in this Amendment have the meanings given to them in the Agreement (as defined below).

WHEREAS, the Company and Executive are parties

to that certain Employment Agreement dated as of November 1, 2024 (the “Agreement”); and

WHEREAS, the Company and Executive desire to amend

the Agreement as set forth herein, and the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”)

and the Board of Directors of the Company (the “Board”) have approved this Amendment.

NOW, THEREFORE, in consideration of the mutual

covenants herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties

agree as follows:

1. Position. Section 1(b) of the Agreement

is amended and restated in its entirety to read as follows:

“(b) During the Period

of Employment, Executive shall serve as President and Chief Scientific Officer of the Company and shall have the powers, authorities and

duties customarily vested in such offices in the industry of the Company and as reasonably determined by the Board from time to time.

Executive shall continue to serve as a member of the Board, subject to the Company’s Certificate of Incorporation and Bylaws and

applicable law.”

Executive acknowledges and consents to the foregoing

change in position and to the appointment of another individual as Chief Executive Officer of the Company, and agrees that none of the

foregoing constitutes Good Reason under the Agreement as in effect before or after this Amendment.

2. Compensation. Sections 3(a), 3(b), 3(d)

and 3(e) of the Agreement are amended and restated in their entirety to read as follows, and Section 3(c) of the Agreement is unchanged:

“(a) Base Salary. Executive’s

current annual Base Salary is US$250,000, payable on the Company’s normal payroll schedule. Base Salary shall increase automatically,

without further Board or Compensation Committee action, to $400,000 when Cumulative Qualifying Funding first exceeds $35,000,000; to $450,000

when it first exceeds $55,000,000; and to $525,000 when it first exceeds $75,000,000. “Cumulative Qualifying Funding” means

the aggregate cash actually received by the Company or its controlled subsidiaries on or after the Amendment Effective Date (as defined

in Amendment No. 1 to this Agreement) through equity investments (including PIPEs), strategic investments, grants, licensing or partnership

upfront payments and milestone payments, acquisition-related net cash proceeds, acquired unrestricted cash that becomes available to the

Company, and other business-development financing transactions. Amounts shall count once only, net of amounts returned, refunded or cancelled;

announced deal values, contingent unpaid consideration and undrawn credit facilities do not count until received. Separate tranches count

when received; multiple qualifying transactions aggregate. The increased Base Salary becomes effective on the date the applicable threshold

is exceeded and any retroactive payroll difference shall be paid in the next practicable payroll, no later than 30 days thereafter. Once

attained, any Base Salary level is permanent and shall never be reduced, including as part of an across-the-board reduction, due to later

expenditures or declines in cash balance, or otherwise, without Executive’s express written consent. The Board may increase but

shall not decrease Base Salary. The Company shall maintain and provide Executive on reasonable request an accounting of qualifying receipts.

The parties acknowledge that a portion of Base Salary constitutes consideration for the enforceable covenants under Section 6.

(b) Annual Cash Bonus. Executive

shall have an annual target cash bonus opportunity (the “Annual Bonus”) equal to sixty percent (60%) of Base Salary for the

fiscal year ending December 31, 2026 and thereafter no less than fifty-five percent (55%) and up to seventy percent (70%) of Base Salary,

with the annual target percentage established in writing by the Compensation Committee of the Board (the “Compensation Committee”)

no later than 60 days after the start of each fiscal year; absent timely written adjustment, the target shall remain 60%, and no decrease

below a prior approved higher target may occur without Executive’s written consent. The Compensation Committee shall establish objective,

reasonably achievable financial, clinical, operational, strategic-transaction and individual performance objectives after consultation

with Executive. Achievement above target may merit payment above target pursuant to an approved bonus program. Bonuses shall be calculated

using Base Salary actually earned during the fiscal year, accounting for salary accelerators, and shall be paid no later than March 15

of the following year, subject to legally required deferral provisions. On a termination without Cause or resignation for Good Reason,

Executive shall receive a prorated target Annual Bonus for the termination year, payable under Section 5(c). Any Annual Bonus for a completed

performance year shall remain payable notwithstanding separation before the ordinary payment date, except termination for Cause.

(d) Reimbursement of Business

Expenses. The Company shall reimburse reasonable, documented expenses incurred for Company business, including air and ground travel,

appropriate lodging, communications, professional memberships, investor/partner meetings, and reasonable meals and entertainment. Executive

may book reasonable executive-level accommodations consistent with Company resources and business needs. No relocation shall be required.

Reimbursement shall be made within 30 days after submission of documentation (or earlier when required by law); advance approval rules

must be reasonable, disclosed in writing and not applied retroactively.

(e) Clawback Policy. To the extent

required by applicable law or regulation, any applicable stock exchange listing standards or any clawback policy adopted by the Company

pursuant to any such law, regulation or stock exchange listing standards (including, without limitation, the Company’s compensation

recovery policy adopted pursuant to Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule

10D-1 thereunder and Nasdaq Listing Rule 5608, as in effect from time to time), or to comport with good corporate governance practices,

the Annual Bonus and any other incentive compensation granted to Executive (whether pursuant to this Employment Agreement or otherwise)

shall be subject to the provisions of any applicable clawback policies or procedures, which may provide for forfeiture and/or recoupment

of such amounts paid or payable under this Employment Agreement or otherwise, including incentive equity awards granted to Executive.”

3. Employee Benefits. Section 4(a) of the

Agreement is amended and restated in its entirety to read as follows:

“(a) Company Employee Benefit

Plans. During the Period of Employment, Executive and Executive’s eligible dependents shall be eligible to participate in all health,

dental, vision, life, disability and retirement programs available to similarly situated executives of the Company, subject to applicable

plan terms, and to receive benefits no less favorable than those afforded to other senior officers of the Company. The Company may modify

generally applicable plans in compliance with law, but shall not selectively reduce Executive’s contractual compensation or negotiated

rights. The Company shall provide a current written summary of available coverage, premium sharing and eligibility upon Executive’s

request.”

2

4. Severance. Sections 5(c)(ii), 5(c)(iii)

and 5(c)(iv) of the Agreement are amended and restated in their entirety to read as follows, and Section 5(c)(v) of the Agreement is deleted:

“(ii) If, during the Period

of Employment, Executive’s employment with the Company ends as a result of an involuntary termination by the Company without Cause

or Executive’s resignation for Good Reason other than in connection with a Change in Control, then, in addition to the amounts payable

under Section 5(c)(i), subject to Executive’s timely execution and non-revocation of the general release described in Section 5(d)

(the “General Release”) and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve

(12) months of Base Salary (at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good

Reason triggered by a reduction in Base Salary, the rate in effect prior to the reduction), payable in substantially equal installments

on each of the Company’s regular payroll payment dates during the twelve (12) months following the Separation Date; (B) to the extent

unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding the year in which the Separation Date occurs,

payable at the time such Annual Bonus would otherwise have been paid under Section 3(b); (C) a prorated target Annual Bonus for the fiscal

year in which the Separation Date occurs, payable in a lump sum on the first regular payroll date following the effectiveness of the General

Release; and (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums

for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon

Executive’s eligibility for substantially comparable employer-sponsored coverage ((A) through (D) collectively, the “Severance

Payments”); provided, that no installment or portion of the Severance Payments shall be payable or paid until the expiration of

the applicable revocation period for the General Release. Notwithstanding anything herein to the contrary, if any Severance Payment is

“nonqualified deferred compensation” within the meaning of Section 409A and the period to consider and, if applicable, revoke

the General Release plus the first regular payroll date thereafter spans two calendar years, then no portion of the Severance Payments

shall be paid until the Company’s first payroll payment date in the second calendar year, and any amount not paid prior to such

date due to such restriction shall be paid in a lump sum along with the installment scheduled to be paid on that date.

(iii) If Executive’s employment

is terminated by the Company without Cause or by Executive for Good Reason within the ninety (90) days prior to a Change in Control or

within the twelve (12) months following a Change in Control, then, in addition to the amounts payable under Section 5(c)(i) but in lieu

of the Severance Payments payable under Section 5(c)(ii), subject to Executive’s timely execution and non-revocation of the General

Release and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve (12) months of Base Salary

(at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good Reason triggered by a reduction

in Base Salary, the rate in effect prior to the reduction), payable in a lump sum on the first regular payroll date following the effectiveness

of the General Release; (B) to the extent unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding

the year in which the Separation Date occurs, payable at the time such Annual Bonus would otherwise have been paid under Section 3(b);

(C) a lump-sum payment, payable on the first regular payroll date following the effectiveness of the General Release, equal to one hundred

percent (100%) of Executive’s target Annual Bonus for the fiscal year in which the Separation Date occurs (which amount shall not

be prorated); (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums

for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon

Executive’s eligibility for substantially comparable employer-sponsored coverage; and (E) acceleration of one hundred percent (100%)

of Executive’s outstanding unvested equity awards as of the Separation Date; provided, however, that if an outstanding equity award

is to vest and/or the amount of the equity award to vest is to be determined based on the achievement of performance criteria, then the

equity award will vest as to one hundred percent (100%) of the amount of the equity award assuming the performance criteria had been achieved

at target levels for the relevant performance period(s), unless otherwise provided in the applicable award agreement ((A) through (E)

collectively, the “Change in Control Severance Payments”). For a qualifying termination occurring prior to a Change in Control,

any equity award that was forfeited on the Separation Date shall be treated as having remained outstanding through the closing of the

Change in Control for purposes of this clause (E), to the extent permitted by the applicable plan.

3

(iv) A material, finally determined

breach by Executive of enforceable continuing obligations under Section 6, after written notice and a reasonable opportunity to cure where

curable, may permit only prospective suspension of amounts not legally protected, subject to applicable law and judicial review. Accrued

wages, earned bonuses, vested equity and indemnification rights shall not be forfeited solely by allegation of breach.”

5. Exclusive Remedy. Section 5(e) of the

Agreement is amended and restated in its entirety to read as follows:

“(e) Exclusive Remedy.

Section 5(c) provides the parties’ agreed contractual severance treatment but shall not preclude Executive from enforcing this Agreement,

exercising vested equity rights, recovering accrued salary or earned bonuses, asserting indemnification or advancement rights, seeking

relief for discrimination, retaliation or other statutory violations, or pursuing benefits expressly protected by applicable law. Nothing

herein requires waiver of claims that cannot legally be waived.”

6. Certain Defined Terms. Sections 5(f)(ii)

and 5(f)(v) of the Agreement are amended and restated in their entirety to read as follows:

“(ii) “Cause”

means (A) final conviction of or guilty/nolo contendere plea to a felony involving dishonesty or material harm to the Company or its affiliates

or subsidiaries (the “Company Group” and each a “Company Group Member”); (B) willful fraud, theft or embezzlement

against the Company Group; (C) willful and material failure to perform lawful duties as President and Chief Scientific Officer after a

specific written demand identifying the deficiency and at least thirty (30) days to cure where curable; (D) willful and material breach

of this Agreement or a material written Company policy applicable to senior executives, after thirty (30) days’ written notice and

opportunity to cure where curable; or (E) willful misconduct or gross negligence resulting in demonstrable material harm to the Company

Group. An act is not “willful” if undertaken in good faith with a reasonable belief that it served the Company’s interests.

No termination for Cause shall occur without written particulars and a reasonable opportunity for Executive and counsel to respond to

disinterested Board members. Executive shall recuse himself from the Board’s determination. Cause shall not include mere business

disagreement, an unsuccessful good-faith strategic decision, or failure to meet results in the absence of misconduct. Notwithstanding

the foregoing, no Cause shall exist unless the Company has provided the Executive written notice detailing the event constituting Cause

and, to the extent the event is reasonably susceptible to cure, the Executive does not cure such event within thirty (30) days of the

receipt of such notice.

(v) “Good Reason” means,

without Executive’s prior written consent: (A) any reduction in Base Salary (except for a decrease of not more than ten percent

(10%) in connection with any across-the-board reduction impacting substantially all executives of the Company); (B) a material decrease

in the target Annual Bonus opportunity; (C) material diminution of Executive’s responsibilities, authority or status as President

and Chief Scientific Officer; (D) required relocation of Executive’s principal work location by more than twenty-five (25) miles;

(E) material breach of this Agreement by the Company, including repeated failure to pay amounts when due; or (F) failure of a successor

to assume this Agreement. Executive shall notify the Company within ninety (90) days after learning of the condition, the Company shall

have thirty (30) days to cure, and Executive shall terminate within ninety (90) days following expiration of the cure period if uncured.”

4

7. Resignations. Section 5(g) of the Agreement

is amended and restated in its entirety to read as follows:

“(g) Officer/Board/Committee

Resignations. Upon termination of employment, Executive shall resign from Company officer positions, but a resignation from the Board

shall be subject to applicable law, the Company’s governing documents and any separately negotiated Board transition arrangement.

No deemed resignation shall deprive Executive of rights arising from a Company-initiated removal that constitutes Good Reason, or of accrued

equity, indemnification or advancement rights.”

8. Cross-References. The references to

“Section 3(c)” in Sections 5(f)(i) and 5(h)(iii) of the Agreement are each replaced with “Section 3(d)”.

9. Consent to Jurisdiction. Section 12

of the Agreement is amended and restated in its entirety to read as follows:

“12. Consent to Jurisdiction.

Subject to mandatory statutory venue and jurisdiction rules, the parties consent to the state and federal courts located in California

for claims arising from this Agreement, and waive objections to personal jurisdiction where lawful. Either party may seek provisional

equitable relief in an otherwise competent court, without waiving available defenses or statutory rights. Service of process shall comply

with applicable law. Nothing herein limits a right to pursue a claim before an administrative agency.”

10. Indemnification. Section 15 of the

Agreement is amended and restated in its entirety to read as follows:

“15. Indemnification. To

the fullest extent permitted by Delaware law and the Company’s governing documents, the Company shall indemnify Executive for actions

taken in good faith in Executive’s capacity as an officer and director of the Company, and shall advance reasonable defense expenses

promptly upon appropriate undertaking where legally required. The Company and Executive shall enter into a separate written indemnification

agreement no less favorable than those of the Company’s other directors and executive officers. The Company shall maintain commercially

reasonable directors’ and officers’ liability insurance covering Executive on terms no less favorable than other senior officers

and directors throughout service and, for claims relating to such service, appropriate run-off/tail coverage for at least six (6) years

following a Change in Control, subject to commercially reasonable availability and cost. Executive may use independent counsel at Company

expense when an actual material conflict warrants it, to the extent legally permitted. These obligations survive termination.”

11. Entire Agreement; Amendment. Section

16 of the Agreement is amended and restated in its entirety to read as follows:

“16. Entire Agreement; Amendment.

This Agreement (as amended by Amendment No. 1 hereto), the award agreement(s) evidencing any equity awards granted to Executive,

the separate indemnification agreement, any Wage Deferral Agreement and Acknowledgment between the Company and Executive and the completed

Exhibit A hereto embody the entire agreement of the parties hereto respecting the matters within their scope and supersede all prior

agreements, whether written or oral, that directly or indirectly bear upon the subject matter hereof, excluding any restrictive covenant

agreement by and between Executive and any Company Group Member. This Agreement may not be amended, modified or changed (in whole or

in part), except by written agreement executed by Executive and a duly authorized officer of the Company following any required approval

of the Board or the Compensation Committee.”

5

12. Notices. The address of the Company

for notices under Section 19 of the Agreement is amended to read as follows: Estrella Immunopharma, Inc., 5858 Horton Street, Suite 370,

Emeryville, CA 94608, Attention: Chief Financial Officer.

13. Base Salary Deferral. Executive acknowledges

that, in order to preserve the Company’s cash resources pending the completion of additional financing, the Company has deferred

payment of Executive’s Base Salary beginning with the May 22, 2026 pay date, and that Executive has agreed to enter into a Wage

Deferral Agreement and Acknowledgment with the Company documenting such deferral on the terms approved by the Compensation Committee and

the Board. Executive agrees that such deferral, as applied to Base Salary as adjusted by this Amendment, does not constitute a reduction

in Base Salary, a breach of the Agreement by the Company or Good Reason, and that nothing in this Amendment accelerates the payment of

any amount so deferred.

14. Effect of Amendment. Except as expressly

amended by this Amendment, the Agreement remains in full force and effect, and from and after the Amendment Effective Date all references

in the Agreement to the “Agreement” shall mean the Agreement as amended by this Amendment. This Amendment shall be governed

by the law governing the Agreement and may be executed in counterparts, including by electronic signature, each of which shall be deemed

an original and all of which together shall constitute one instrument.

[Signature page follows]

6

IN WITNESS WHEREOF, the parties have executed

this Amendment No. 1 to Employment Agreement as of the Amendment Effective Date.

COMPANY:

EXECUTIVE:

Estrella Immunopharma, Inc.

By:

/s/ Peter Xu

/s/ Cheng Liu

Name:

Peter Xu

Cheng Liu

Title:

Chief Financial Officer

Date:

October 25, 2026

Date: October 25, 2026

[Signature Page to Amendment No. 1 to Employment

Agreement]

7

EX-10.3 — AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT, DATED AS OF OCTOBER 25, 2026, BY AND BETWEEN ESTRELLA IMMUNOPHARMA, INC. AND JIANDONG (PETER) XU

EX-10.3

Filename: ea031020901ex10-3.htm · Sequence: 4

Exhibit 10.3

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

This Amendment No. 1 to Employment Agreement (this

“Amendment”) is made and entered into effective as of October 25, 2026 (the “Amendment Effective Date”), by and

between Estrella Immunopharma, Inc., a Delaware corporation (the “Company”), and Jiandong (Peter) Xu (“Executive”).

Capitalized terms used but not defined in this Amendment have the meanings given to them in the Agreement (as defined below).

WHEREAS, the Company and Executive are parties

to that certain Employment Agreement dated as of September 29, 2023 (the “Agreement”); and

WHEREAS, the Company and Executive desire to amend

the Agreement as set forth herein, and the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”)

and the Board of Directors of the Company (the “Board”) have approved this Amendment.

NOW, THEREFORE, in consideration of the mutual

covenants herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties

agree as follows:

1. Compensation. Sections 3(a), 3(b), 3(d)

and 3(e) of the Agreement are amended and restated in their entirety to read as follows, and Section 3(c) of the Agreement is unchanged:

“(a) Base Salary. Executive’s

current annual Base Salary is US$250,000, payable on the Company’s normal payroll schedule. Base Salary shall increase automatically,

without further Board or Compensation Committee action, to $400,000 when Cumulative Qualifying Funding first exceeds $35,000,000; to $450,000

when it first exceeds $55,000,000; and to $525,000 when it first exceeds $75,000,000. “Cumulative Qualifying Funding” means

the aggregate cash actually received by the Company or its controlled subsidiaries on or after the Amendment Effective Date (as defined

in Amendment No. 1 to this Agreement) through equity investments (including PIPEs), strategic investments, grants, licensing or partnership

upfront payments and milestone payments, acquisition-related net cash proceeds, acquired unrestricted cash that becomes available to the

Company, and other business-development financing transactions. Amounts shall count once only, net of amounts returned, refunded or cancelled;

announced deal values, contingent unpaid consideration and undrawn credit facilities do not count until received. Separate tranches count

when received; multiple qualifying transactions aggregate. The increased Base Salary becomes effective on the date the applicable threshold

is exceeded and any retroactive payroll difference shall be paid in the next practicable payroll, no later than 30 days thereafter. Once

attained, any Base Salary level is permanent and shall never be reduced, including as part of an across-the-board reduction, due to later

expenditures or declines in cash balance, or otherwise, without Executive’s express written consent. The Board may increase but

shall not decrease Base Salary. The Company shall maintain and provide Executive on reasonable request an accounting of qualifying receipts.

The parties acknowledge that a portion of Base Salary constitutes consideration for the enforceable covenants under Section 6.

(b) Annual Cash Bonus. Executive

shall have an annual target cash bonus opportunity (the “Annual Bonus”) equal to sixty percent (60%) of Base Salary for the

fiscal year ending December 31, 2026 and thereafter no less than fifty-five percent (55%) and up to seventy percent (70%) of Base Salary,

with the annual target percentage established in writing by the Compensation Committee of the Board (the “Compensation Committee”)

no later than 60 days after the start of each fiscal year; absent timely written adjustment, the target shall remain 60%, and no decrease

below a prior approved higher target may occur without Executive’s written consent. The Compensation Committee shall establish objective,

reasonably achievable financial, clinical, operational, strategic-transaction and individual performance objectives after consultation

with Executive. Achievement above target may merit payment above target pursuant to an approved bonus program. Bonuses shall be calculated

using Base Salary actually earned during the fiscal year, accounting for salary accelerators, and shall be paid no later than March 15

of the following year, subject to legally required deferral provisions. On a termination without Cause or resignation for Good Reason,

Executive shall receive a prorated target Annual Bonus for the termination year, payable under Section 5(c). Any Annual Bonus for a completed

performance year shall remain payable notwithstanding separation before the ordinary payment date, except termination for Cause.

(d) Reimbursement of Business

Expenses. The Company shall reimburse reasonable, documented expenses incurred for Company business, including air and ground travel,

appropriate lodging, communications, professional memberships, investor/partner meetings, and reasonable meals and entertainment. Executive

may book reasonable executive-level accommodations consistent with Company resources and business needs. No relocation shall be required.

Reimbursement shall be made within 30 days after submission of documentation (or earlier when required by law); advance approval rules

must be reasonable, disclosed in writing and not applied retroactively.

(e) Clawback Policy. To the extent

required by applicable law or regulation, any applicable stock exchange listing standards or any clawback policy adopted by the Company

pursuant to any such law, regulation or stock exchange listing standards (including, without limitation, the Company’s compensation

recovery policy adopted pursuant to Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Rule

10D-1 thereunder and Nasdaq Listing Rule 5608, as in effect from time to time), or to comport with good corporate governance practices,

the Annual Bonus and any other incentive compensation granted to Executive (whether pursuant to this Employment Agreement or otherwise)

shall be subject to the provisions of any applicable clawback policies or procedures, which may provide for forfeiture and/or recoupment

of such amounts paid or payable under this Employment Agreement or otherwise, including incentive equity awards granted to Executive.”

2. Employee Benefits. Section 4(a) of the

Agreement is amended and restated in its entirety to read as follows:

“(a) Company Employee Benefit

Plans. During the Period of Employment, Executive and Executive’s eligible dependents shall be eligible to participate in all health,

dental, vision, life, disability and retirement programs available to similarly situated executives of the Company, subject to applicable

plan terms, and to receive benefits no less favorable than those afforded to other senior officers of the Company. The Company may modify

generally applicable plans in compliance with law, but shall not selectively reduce Executive’s contractual compensation or negotiated

rights. The Company shall provide a current written summary of available coverage, premium sharing and eligibility upon Executive’s

request.”

2

3. Severance. Sections 5(c)(ii), 5(c)(iii)

and 5(c)(iv) of the Agreement are amended and restated in their entirety to read as follows, and Section 5(c)(v) of the Agreement is deleted:

“(ii) If, during the Period

of Employment, Executive’s employment with the Company ends as a result of an involuntary termination by the Company without Cause

or Executive’s resignation for Good Reason other than in connection with a Change in Control, then, in addition to the amounts payable

under Section 5(c)(i), subject to Executive’s timely execution and non-revocation of the general release described in Section 5(d)

(the “General Release”) and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve

(12) months of Base Salary (at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good

Reason triggered by a reduction in Base Salary, the rate in effect prior to the reduction), payable in substantially equal installments

on each of the Company’s regular payroll payment dates during the twelve (12) months following the Separation Date; (B) to the extent

unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding the year in which the Separation Date occurs,

payable at the time such Annual Bonus would otherwise have been paid under Section 3(b); (C) a prorated target Annual Bonus for the fiscal

year in which the Separation Date occurs, payable in a lump sum on the first regular payroll date following the effectiveness of the General

Release; and (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums

for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon

Executive’s eligibility for substantially comparable employer-sponsored coverage ((A) through (D) collectively, the “Severance

Payments”); provided, that no installment or portion of the Severance Payments shall be payable or paid until the expiration of

the applicable revocation period for the General Release. Notwithstanding anything herein to the contrary, if any Severance Payment is

“nonqualified deferred compensation” within the meaning of Section 409A and the period to consider and, if applicable, revoke

the General Release plus the first regular payroll date thereafter spans two calendar years, then no portion of the Severance Payments

shall be paid until the Company’s first payroll payment date in the second calendar year, and any amount not paid prior to such

date due to such restriction shall be paid in a lump sum along with the installment scheduled to be paid on that date.

(iii) If Executive’s employment

is terminated by the Company without Cause or by Executive for Good Reason within the ninety (90) days prior to a Change in Control or

within the twelve (12) months following a Change in Control, then, in addition to the amounts payable under Section 5(c)(i) but in lieu

of the Severance Payments payable under Section 5(c)(ii), subject to Executive’s timely execution and non-revocation of the General

Release and the other conditions and limitations herein, Executive shall be entitled to receive (A) twelve (12) months of Base Salary

(at the rate in effect immediately prior to the Separation Date or, if the termination is as a result of Good Reason triggered by a reduction

in Base Salary, the rate in effect prior to the reduction), payable in a lump sum on the first regular payroll date following the effectiveness

of the General Release; (B) to the extent unpaid as of the Separation Date, the Annual Bonus for the fiscal year immediately preceding

the year in which the Separation Date occurs, payable at the time such Annual Bonus would otherwise have been paid under Section 3(b);

(C) a lump-sum payment, payable on the first regular payroll date following the effectiveness of the General Release, equal to one hundred

percent (100%) of Executive’s target Annual Bonus for the fiscal year in which the Separation Date occurs (which amount shall not

be prorated); (D) if Executive timely elects COBRA continuation coverage, payment or reimbursement of the employer portion of the premiums

for Executive and Executive’s covered dependents for up to twelve (12) months following the Separation Date, ending earlier upon

Executive’s eligibility for substantially comparable employer-sponsored coverage; and (E) acceleration of one hundred percent (100%)

of Executive’s outstanding unvested equity awards as of the Separation Date; provided, however, that if an outstanding equity award

is to vest and/or the amount of the equity award to vest is to be determined based on the achievement of performance criteria, then the

equity award will vest as to one hundred percent (100%) of the amount of the equity award assuming the performance criteria had been achieved

at target levels for the relevant performance period(s), unless otherwise provided in the applicable award agreement ((A) through (E)

collectively, the “Change in Control Severance Payments”). For a qualifying termination occurring prior to a Change in Control,

any equity award that was forfeited on the Separation Date shall be treated as having remained outstanding through the closing of the

Change in Control for purposes of this clause (E), to the extent permitted by the applicable plan.

3

(iv) A material, finally determined

breach by Executive of enforceable continuing obligations under Section 6, after written notice and a reasonable opportunity to cure where

curable, may permit only prospective suspension of amounts not legally protected, subject to applicable law and judicial review. Accrued

wages, earned bonuses, vested equity and indemnification rights shall not be forfeited solely by allegation of breach.”

4. Exclusive Remedy. Section 5(e) of the

Agreement is amended and restated in its entirety to read as follows:

“(e) Exclusive Remedy.

Section 5(c) provides the parties’ agreed contractual severance treatment but shall not preclude Executive from enforcing this Agreement,

exercising vested equity rights, recovering accrued salary or earned bonuses, asserting indemnification or advancement rights, seeking

relief for discrimination, retaliation or other statutory violations, or pursuing benefits expressly protected by applicable law. Nothing

herein requires waiver of claims that cannot legally be waived.”

5. Certain Defined Terms. Sections 5(f)(ii)

and 5(f)(v) of the Agreement are amended and restated in their entirety to read as follows:

“(ii) “Cause”

means (A) final conviction of or guilty/nolo contendere plea to a felony involving dishonesty or material harm to the Company or its affiliates

or subsidiaries (the “Company Group” and each a “Company Group Member”); (B) willful fraud, theft or embezzlement

against the Company Group; (C) willful and material failure to perform lawful duties as Chief Financial Officer after a specific written

demand identifying the deficiency and at least thirty (30) days to cure where curable; (D) willful and material breach of this Agreement

or a material written Company policy applicable to senior executives, after thirty (30) days’ written notice and opportunity to

cure where curable; or (E) willful misconduct or gross negligence resulting in demonstrable material harm to the Company Group. An act

is not “willful” if undertaken in good faith with a reasonable belief that it served the Company’s interests. No termination

for Cause shall occur without written particulars and a reasonable opportunity for Executive and counsel to respond to disinterested Board

members. If Executive is then a member of the Board, Executive shall recuse himself from the Board’s determination. Cause shall

not include mere business disagreement, an unsuccessful good-faith strategic decision, or failure to meet results in the absence of misconduct.

Notwithstanding the foregoing, no Cause shall exist unless the Company has provided the Executive written notice detailing the event constituting

Cause and, to the extent the event is reasonably susceptible to cure, the Executive does not cure such event within thirty (30) days of

the receipt of such notice.

4

(v) “Good Reason” means,

without Executive’s prior written consent: (A) any reduction in Base Salary (except for a decrease of not more than ten percent

(10%) in connection with any across-the-board reduction impacting substantially all executives of the Company); (B) a material decrease

in the target Annual Bonus opportunity; (C) material diminution of Executive’s responsibilities, authority or status as Chief Financial

Officer; (D) required relocation of Executive’s principal work location by more than twenty-five (25) miles; (E) material breach

of this Agreement by the Company, including repeated failure to pay amounts when due; or (F) failure of a successor to assume this Agreement.

Executive shall notify the Company within ninety (90) days after learning of the condition, the Company shall have thirty (30) days to

cure, and Executive shall terminate within ninety (90) days following expiration of the cure period if uncured.”

6. Resignations. Section 5(g) of the Agreement

is amended and restated in its entirety to read as follows:

“(g) Officer/Board/Committee

Resignations. Upon termination of employment, Executive shall resign from all officer positions with the Company Group and from any position

as a fiduciary of any employee benefit plan of the Company Group. No deemed resignation shall deprive Executive of rights arising from

a Company-initiated removal that constitutes Good Reason, or of accrued equity, indemnification or advancement rights.”

7. Cross-References. The references to

“Section 3(c)” in Sections 5(f)(i) and 5(h)(iii) of the Agreement are each replaced with “Section 3(d)”.

8. Consent to Jurisdiction. Section 11

of the Agreement is amended and restated in its entirety to read as follows:

“11. Consent to Jurisdiction.

Subject to mandatory statutory venue and jurisdiction rules, the parties consent to the state and federal courts located in California

for claims arising from this Agreement, and waive objections to personal jurisdiction where lawful. Either party may seek provisional

equitable relief in an otherwise competent court, without waiving available defenses or statutory rights. Service of process shall comply

with applicable law. Nothing herein limits a right to pursue a claim before an administrative agency.”

9. Indemnification. Section 14 of the Agreement

is amended and restated in its entirety to read as follows:

“14. Indemnification. To

the fullest extent permitted by Delaware law and the Company’s governing documents, the Company shall indemnify Executive for actions

taken in good faith in Executive’s capacity as an officer of the Company, and shall advance reasonable defense expenses promptly

upon appropriate undertaking where legally required. The Company and Executive shall enter into a separate written indemnification agreement

no less favorable than those of the Company’s other directors and executive officers. The Company shall maintain commercially reasonable

directors’ and officers’ liability insurance covering Executive on terms no less favorable than other senior officers and

directors throughout service and, for claims relating to such service, appropriate run-off/tail coverage for at least six (6) years following

a Change in Control, subject to commercially reasonable availability and cost. Executive may use independent counsel at Company expense

when an actual material conflict warrants it, to the extent legally permitted. These obligations survive termination.”

5

10. Entire Agreement; Amendment. Section

15 of the Agreement is amended and restated in its entirety to read as follows:

“15. Entire Agreement; Amendment.

This Agreement (as amended by Amendment No. 1 hereto), the award agreement(s) evidencing any equity awards granted to Executive,

the separate indemnification agreement, any Wage Deferral Agreement and Acknowledgment between the Company and Executive and the completed

Exhibit A hereto embody the entire agreement of the parties hereto respecting the matters within their scope and supersede all prior

agreements, whether written or oral, that directly or indirectly bear upon the subject matter hereof, excluding any restrictive covenant

agreement by and between Executive and any Company Group Member. This Agreement may not be amended, modified or changed (in whole or

in part), except by written agreement executed by Executive and a duly authorized officer of the Company following any required approval

of the Board or the Compensation Committee.”

11. Notices. The address of the Company

for notices under Section 18 of the Agreement is amended to read as follows: Estrella Immunopharma, Inc., 5858 Horton Street, Suite 370,

Emeryville, CA 94608, Attention: Chief Executive Officer.

12. Base Salary Deferral. Executive acknowledges

that, in order to preserve the Company’s cash resources pending the completion of additional financing, the Company has deferred

payment of Executive’s Base Salary beginning with the May 22, 2026 pay date, and that Executive has agreed to enter into a Wage

Deferral Agreement and Acknowledgment with the Company documenting such deferral on the terms approved by the Compensation Committee and

the Board. Executive agrees that such deferral, as applied to Base Salary as adjusted by this Amendment, does not constitute a reduction

in Base Salary, a breach of the Agreement by the Company or Good Reason, and that nothing in this Amendment accelerates the payment of

any amount so deferred.

13. Effect of Amendment. Except as expressly

amended by this Amendment, the Agreement remains in full force and effect, and from and after the Amendment Effective Date all references

in the Agreement to the “Agreement” shall mean the Agreement as amended by this Amendment. This Amendment shall be governed

by the law governing the Agreement and may be executed in counterparts, including by electronic signature, each of which shall be deemed

an original and all of which together shall constitute one instrument.

[Signature page follows]

6

IN WITNESS WHEREOF, the parties have executed

this Amendment No. 1 to Employment Agreement as of the Amendment Effective Date.

EXECUTIVE:

COMPANY:

Estrella Immunopharma, Inc.

By:

/s/ Cheng Liu

/s/ Jiandong (Peter) Xu

Name:

Cheng Liu

Jiandong (Peter) Xu

Title:

President and Chief Scientific Officer

Date: October 25, 2026

Date: October 25, 2026

[Signature Page to Amendment No. 1 to Employment

Agreement]

7

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 10

v3.26.3

Cover

Oct. 25, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 25, 2026

Entity File Number

001-40608

Entity Registrant Name

ESTRELLA IMMUNOPHARMA, INC.

Entity Central Index Key

0001844417

Entity Tax Identification Number

86-1314502

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

5858 Horton Street

Entity Address, Address Line Two

Suite 370

Entity Address, City or Town

Emeryville

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

94608

City Area Code

510

Local Phone Number

318-9098

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

ESLA

Security Exchange Name

NASDAQ

Warrants, each warrant exercisable for one share of Common Stock, each at an exercise price of $11.50 per share

Title of 12(b) Security

Warrants, each warrant exercisable for one share of Common Stock, each at an exercise price of $11.50 per share

Trading Symbol

ESLAW

Security Exchange Name

NASDAQ

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=ESLA_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=ESLA_WarrantsEachWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type: